ArticleCancer reports (Hoboken, N.J.)2021

Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.

Zentaro Saito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.